BioXcel Therapeutics annual return on equity
2018
2019
2020
2021
2022
2023
BioXcel Therapeutics Return on Equity (ROE) Growth & History (BTAI)
BioXcel Therapeutics's return on equity was −1,766.94% for fiscal 2023.
View full BioXcel Therapeutics company overviewBioXcel Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −1,766.94% | −1655.86 pp |
| 2022 | 2022-12-31 | −111.08% | −61.16 pp |
| 2021 | 2021-12-31 | −49.93% | +20.43 pp |
| 2020 | 2020-12-31 | −70.35% | +29.88 pp |
| 2019 | 2019-12-31 | −100.23% | +1.44 pp |
| 2018 | 2018-12-31 | −101.67% | — |
BioXcel Therapeutics quarterly return on equity
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2023 | 2023-06-30 | −181.81% | −160.78 pp |
| Q1 2023 | 2023-03-31 | −81.36% | −66.22 pp |
| Q4 2022 | 2022-12-31 | −53.80% | −42.61 pp |
| Q3 2022 | 2022-09-30 | −28.71% | −18.25 pp |
| Q2 2022 | 2022-06-30 | −21.03% | −8.87 pp |
| Q1 2022 | 2022-03-31 | −15.14% | −1.73 pp |
| Q4 2021 | 2021-12-31 | −11.18% | −1.32 pp |
| Q3 2021 | 2021-09-30 | −10.45% | +7.59 pp |
| Q2 2021 | 2021-06-30 | −12.16% | +21.84 pp |
| Q1 2021 | 2021-03-31 | −13.41% | +16.57 pp |
| Q4 2020 | 2020-12-31 | −9.86% | +17.13 pp |
| Q3 2020 | 2020-09-30 | −18.05% | +12.23 pp |
| Q2 2020 | 2020-06-30 | −34.00% | −4.55 pp |
| Q1 2020 | 2020-03-31 | −29.98% | −9.76 pp |
| Q4 2019 | 2019-12-31 | −26.99% | −10.29 pp |
| Q3 2019 | 2019-09-30 | −30.27% | −20.05 pp |
| Q2 2019 | 2019-06-30 | −29.45% | −23.51 pp |
| Q1 2019 | 2019-03-31 | −20.22% | −3.47 pp |
| Q4 2018 | 2018-12-31 | −16.70% | — |
| Q3 2018 | 2018-09-30 | −10.22% | — |
| Q2 2018 | 2018-06-30 | −5.94% | — |
| Q1 2018 | 2018-03-31 | −16.75% | — |
BioXcel Therapeutics return on equity trends
Over the last five fiscal years, BioXcel Therapeutics's return on equity decreased from −101.67% to −1,766.94%, a change of −1665.27 percentage points. The latest reported quarter, Q2 2023, shows −181.81%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioXcel Therapeutics source filings ↗